04:14 PM EDT, 09/14/2022 (MT Newswires) -- Qiagen (QGEN) and biotech company Neuron23 said Wednesday that they have launched a collaboration project to develop a companion diagnostic for Neuron23's drug candidate to treat Parkinson's disease.
The project will back the clinical development of Neuron23's brain penetrant leucine-rich repeat kinase inhibitor, which is in the late stages of preclinical development, the companies said.
The agreement also includes options for the future development of other companion diagnostics.
Financial details were not provided.
Price: 44.97, Change: +0.01, Percent Change: +0.01